Neurological soft signs and response to risperidone in chronic schizophrenia

Biological Psychiatry

Volumn 40, Issue 10, 1996, Pages 1056-1059

  Smith, Robert C ^a,b   Kadewari, Ramesh P ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Dept Psychiatry/MPC ^*  (United States)

Author keywords

atypical neuroleptics; neurological soft signs; nonresponding schizophrenia; risperidone

Indexed keywords

RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; MALE; NEUROLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; RISPERIDONE; SCHIZOPHRENIA;

EID: 0030588999     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00251-X     Document Type: Article

References (12)

1. Alpert M, Pouget E (in preparation): A Scale for the assessment of movement disorders in psychopharmacological studies: The SAMD.
2. Buchanan RW, Heinrichs D (1989): The neurological evaluation scale (NES): A structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res 27:335-350.
3. Buchanan RW, Kirkpatrick B, Heinrichs DW, Carpenter WT (1990): Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry 147:290-294.
4. Buchanan RW, Koppel E, Brier A (1994): Stability of neurological signs with clozapine treatment. Biol Psychiatry 36:198-200.
5. Gupta S, Andreasen NC, Arndt A, et al (1995): Neuroglial soft signs in neuroleptic-naive and neuroleptic treated schizophrenic patients and in normal comparison subjects. Am J Psychiatry 145:191-196.
6. Guy W (1976): ECDU Assessment Manual. Washington, DC: U.S. Govt Printing Office, pp 534-537.
7. Heinrichs D, R. Buchanan (1988): Significance and meaning of neurological signs in schizophrenia. Am J Psychiatry 145:11-17.
8. Kolakowska T, Williams AO, Jambor K, Ardern M (1985): Schizophrenia with good and poor outcome: iii. Neurological 'soft' signs, cognitive impairment and their clinical significance. Br J Psychiatry 146:346-357.
9. Shrout PE, Fleiss JL (1979): Intraclass correlation: Uses in assessing rater reliability. Psychol Bull 86:420-428.
10. Simpson G, Angus J (1970): A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:9-11.
11. Smith RC, Chua JA, Lipetsker B, Bhattacharyya A (in press, 1996): Efficacy of risperidone in reducing positive and negative symptoms in schizophrenia: An open prospective study. J Clin Psychiatry.
12. Vaid G, Smith RC, Rosenberger J, Alter I (1993): Neurological and neuropsychological tests in schizophrenics. Biol Psychiatry 33(suppl 6A):92.